Related references
Note: Only part of the references are listed.Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor-BTK Signaling Pathway
Qian Zhang et al.
JOURNAL OF IMMUNOLOGY (2019)
Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells
Md Kamrul Hasan et al.
LEUKEMIA (2019)
A feedback regulation of CREB activation through the CUL4A and ERK signaling
Cheemala Ashok et al.
MEDICAL ONCOLOGY (2019)
CD5 expression promotes IL-10 production through activation of the MAPK/Erk pathway and upregulation of TRPC1 channels in B lymphocytes
Soizic Garaud et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2018)
Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia
Md Kamrul Hasan et al.
BLOOD (2018)
WNT5A promotes migration and invasion of human osteosarcoma cells via SRC/ERK/MMP-14 pathway
Xingwen Wang et al.
CELL BIOLOGY INTERNATIONAL (2018)
Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia
Michael Y. Choi et al.
CELL STEM CELL (2018)
Dock2 in the development of inflammation and cancer
Yayun Chen et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2018)
Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma
Jian Yu et al.
Oncotarget (2018)
SOS1, ARHGEF1, and DOCK2 rho-GEFs Mediate JAK-Dependent LFA-1 Activation by Chemokines
Lara Toffali et al.
JOURNAL OF IMMUNOLOGY (2017)
Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib
J. Yu et al.
LEUKEMIA (2017)
Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells
M. K. Hasan et al.
LEUKEMIA (2017)
Chronic lymphocytic leukaemia
Thomas J. Kipps et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation
Jian Yu et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia
S-S Chen et al.
LEUKEMIA (2016)
Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL
Ashima Shukla et al.
BLOOD (2016)
High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia
Bing Cui et al.
BLOOD (2016)
Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia
Elisa ten Hacken et al.
JOURNAL OF IMMUNOLOGY (2016)
Unravelling the Mechanism of TrkA-Induced Cell Death by Macropinocytosis in Medulloblastoma Daoy Cells
Chunhui Li et al.
MOLECULAR AND CELLULAR BIOLOGY (2016)
Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1
Michael Y. Choi et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine
Kyle Crassini et al.
LEUKEMIA & LYMPHOMA (2015)
BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia
Niuscha Yaktapour et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity
S. Cheng et al.
LEUKEMIA (2014)
A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics
Apirat Chaikuad et al.
NATURE CHEMICAL BIOLOGY (2014)
ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice
George F. Widhopf et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
The Pathogenesis of Chronic Lymphocytic Leukemia
Suping Zhang et al.
Annual Review of Pathology-Mechanisms of Disease (2013)
Targeting B-cell anergy in chronic lymphocytic leukemia
Benedetta Apollonio et al.
BLOOD (2013)
Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
Erick J. Morris et al.
CANCER DISCOVERY (2013)
The Onco-Embryonic Antigen ROR1 Is Expressed by a Variety of Human Cancers
Suping Zhang et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Blockade of Inflammatory Responses by a Small-Molecule Inhibitor of the Rac Activator DOCK2
Akihiko Nishikimi et al.
CHEMISTRY & BIOLOGY (2012)
ERK1/2 MAP kinases: Structure, function, and regulation
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2012)
Elucidating the CXCL12/CXCR4 Signaling Network in Chronic Lymphocytic Leukemia through Phosphoproteomics Analysis
Morgan O'Hayre et al.
PLOS ONE (2010)
Sequential Regulation of DOCK2 Dynamics by Two Phospholipids During Neutrophil Chemotaxis
Akihiko Nishikimi et al.
SCIENCE (2009)
EPK signaling regulates tumor promoter induced c-Jun recruitment at the Fra-1 promoter
Pavan Adiseshaiah et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia
Sivasubramanian Baskar et al.
CLINICAL CANCER RESEARCH (2008)
Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy
Amir H. DaneshManesh et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal,antigen and receptor for Wnt5a
Tetsuya Fukuda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of rac family small GTPases
Adam Shutes et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Transcriptional regulation of plasminogen activator inhibitor-1 expression by insulin-like growth factor-1 via MAP kinases and hypoxia-inducible factor-1 in HepG2 cells
EY Dimova et al.
THROMBOSIS AND HAEMOSTASIS (2005)
DOCK2 regulates Rac activation and cytoskeletal reorganization through interaction with ELMO1
T Sanui et al.
BLOOD (2003)
Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention
F Chang et al.
LEUKEMIA (2003)
Identification of an evolutionarily conserved superfamily of DOCK180-related proteins with guanine nucleotide exchange activity
JF Côté et al.
JOURNAL OF CELL SCIENCE (2002)
Share Paper
